Ramer Â· Alavi Nuclear Medicine Technology

More documents

Recommendations

Info

12 Neoplasm and Infection Scintigraphy 11910) It is possible to use 99m Tc sestamibi for breast tumorimaging because there is no uptake of sestamibi in thenormal breast.a. trueb. false11) A monoclonal antibody is developed which displayscross-reaction. This means:a. the antibody triggers an immune response in thepatientb. the antibody will bind antigens other than the oneit was formed withc. the antibody can be labeled with either 99m Tcor 111 Ind. none of the above12) Examples of neuroendocrine tumor include:a. pituitary adenomab. small cell lung cancerc. neuroblastomasd. all of the abovee. a and c only13) Visualization of kidneys at 48 hours is on a scanusing 111 In pentetreotide and on a 67 Ga citratescan.a. normal, abnormalb. abnormal, normalc. normal, normald. abnormal, abnormal14) 18 FDG can be used to image tumors because theglycolytic rate is higher in tumor than in normal tissues.a. trueb. false
12012 Neoplasm and Infection Scintigraphy15) Which of the following are true regarding 18 FDG tumorimaging?a. PET scanning is requiredb. the patient should fast before the examc. only brain tumors can be detectedd. all of the abovee. all except c16) On a Monday morning, a technologist learns thata patient needs to be scheduled for imaging with 67 Gacitrate, and also a lower GI. If the ordering physicianwishes that both exams be done within the week,how should these studies be scheduled?a. lower GI on Monday morning, and 67 Ga citrateon Monday afternoonb. lower GI on Monday morning, and 67 Ga citrateon Wednesdayc. 67 Ga injection on Monday morning followed byimaging each day, lower GI at noon on Fridayd. inject patient with 67 Ga citrate on Monday morning,send for lower GI, and then perform first imagingof gallium on Monday afternoon17) Pheochromocytomas are imaged using:a. 131 I MIBGb. 131 I NP-5918) The use of PET imaging in oncology takes advantageof the differences between normal andneoplastic tissue.a. structuralb. metabolicc. densityd. hormonal
Page 5 and 6:
Table of Contents1 Introduction . .
Page 7 and 8:
21 IntroductionIn response to all o
Page 9 and 10:
42 Radioactivity, Radiopharmacy, an
Page 11 and 12:
Page 13:
Page 17 and 18:
122 Radioactivity, Radiopharmacy, a
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
3 Radiation Safety1) Which of the f
Page 27 and 28:
223 Radiation Safety9) Which of the
Page 29 and 30:
243 Radiation Safety18) If the expo
Page 31 and 32:
263 Radiation Safety25) What is the
Page 33 and 34:
283 Radiation Safety33) A technolog
Page 35 and 36:
303 Radiation Safety42) What length
Page 37 and 38:
324 Instrumentation and Quality Ass
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
485 Image Presentation and Computer
Page 55 and 56:
505 Image Presentation and Computer
Page 57 and 58:
6 Skeletal System Scintigraphy1) Wh
Page 59 and 60:
546 Skeletal System Scintigraphy10)
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
7 Central Nervous System Scintigrap
Page 69 and 70:
647 Central Nervous System Scintigr
Page 71 and 72:
667 Central Nervous System Scintigr
Page 73 and 74: 687 Central Nervous System Scintigr
Page 75 and 76: 708 Cardiovascular System Scintigra
Page 91 and 92: 9 Respiratory System Scintigraphy1)
Page 93 and 94: 889 Respiratory System Scintigraphy
Page 101 and 102: 10 Gastrointestinal Tract Scintigra
Page 103 and 104: 9810 Gastrointestinal Tract Scintig
Page 105 and 106: 10010 Gastrointestinal Tract Scinti
Page 111 and 112: 11 Genitourinary System Scintigraph
Page 113 and 114: 10811 Genitourinary System Scintigr
Page 123: 11812 Neoplasm and Infection Scinti
Page 127 and 128: 12212 Neoplasm and Infection Scinti
Page 129 and 130: 12412 Neoplasm and Infection Scinti
Page 131 and 132: 13 Thyroid, Parathyroid,and Salivar
Page 133 and 134: 12813 Thyroid, Parathyroid, and Sal
Page 141 and 142: 14 Non-Imaging Proceduresand Radion
Page 143 and 144: 13814 Non-Imaging Procedures and Ra
Page 151 and 152: 15 Patient Care1) Which of the foll
Page 153 and 154: 14815 Patient Care10) Of the follow
Page 155 and 156: 15015 Patient Care18) According to
Page 157 and 158: 16 Mock Examination1) In which radi
Page 159 and 160: 15416 Mock Examination8) A whole bo
Page 161 and 162: 15616 Mock Examination17) The infer
Page 163 and 164: 15816 Mock ExaminationFigure 16.224
Page 165 and 166: 16016 Mock Examination29) Which of
Page 167 and 168: 16216 Mock Examination37) If a pati
Page 169 and 170: 16416 Mock Examination43) A sentine
Page 171 and 172: 16616 Mock Examination53) First pas
Page 173 and 174: 16816 Mock Examination61) What is t
Page 175 and 176:
17016 Mock Examination71) If a SPEC
Page 177 and 178:
17216 Mock Examination79) When inje
Page 179 and 180:
17416 Mock Examination87) To minimi
Page 181 and 182:
Appendix1761.a2.d3.c4.c5.b6.c7.d8.b
Page 183 and 184:
Appendix1781.c2.b3.d4.b5.c6.c7.b8.c
show all

Ramer Â· Alavi Nuclear Medicine Technology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?